https://finance.yahoo.com/news/89bio-phase-2b-enliven-trial-110000459.html
0
0
89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks - Yahoo Finance
3/22/23 at 11:00am
Organization
Yahoo Entertainment
Authors
89bio Inc.
Details
64 words
Summarize
Business & Industrial Health 89bio Phase 2b ENLIVEN Trial Pegozafermin NASH Primary Histology Endpoints Q2W dose Every-Two-Week fibrosis improvement Yahoo Finance UK effect size
- 44mg Q2W dose had a placebo-adjusted effect size of 20% on at least one-stage fibrosis improvement without worsening of NASH (p=0.008) and 24% on NASH...
Create an account or login to join the discussion